Halozyme Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Helen I. Torley
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12390 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Mar 16, 2004
- CIK
- 0001159036
- Website
- halozyme.com
- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
Halozyme Therapeutics Q2 Earnings Call Highlights
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Amundi
This Medical Technology Stock Claws Back To A Buy Zone
Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech Portfolio
Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High – Here’s What Happened
Halozyme to Report Second Quarter 2026 Financial and Operating Results
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
HALO Inks Deal With INCY to Support Cancer Therapy Development
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Fifth Third Bancorp Grows Position in Halozyme Therapeutics, Inc. $HALO
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy Now
Time for HALO Sectors & ETFs?
Time to Buy Wide Moat & HALO ETFs?